Guangxi HSA Expands Coverage for Assisted Reproductive Medical Services Under BMI
The Healthcare Security Administration (HSA) bureau of the Guangxi Zhuang Autonomous Region has announced a...
Siyi Intelligence Secures Approval for Innovative Rehabilitation Robots in China
Shanghai-based Siyi Intelligence, a developer of soft rehabilitation robots, has announced that it has received...
Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals
China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with...
Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform
Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive...
Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor
Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with...
Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment
Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to...
Staidson Receives NMPA Approval for Clinical Trial of STSA-1301 in Primary Immune Thrombocytopenia
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...
Allist Pharmaceuticals’ Furmonertinib Receives FDA Breakthrough Therapy Designation for NSCLC
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd (SHA: 688578) has announced that it has received breakthrough...
Yirui Pharmaceutical’s YR001 Completes Successful Phase I Clinical Study in the US
Hangzhou-based Yirui Pharmaceutical Technology Co., Ltd has announced the successful conclusion of a Phase I...
Danyang Huichuang Secures Over USD 13.7 Million in Series B Funding for fNIRS Development
Danyang Huichuang Medical Equipment Co., Ltd, a China-based specialist in functional near-infrared spectroscopy (fNIRS), has...
CDE Grants Priority Review to LaNova’s LM-302, Roche’s Alectinib, and Alphamab’s KN026
China’s Center for Drug Evaluation (CDE) has indicated that LaNova Medicines’ LM-302, Roche’s (SWX: ROG)...
Boan Biotech Enrolls First Patient in Phase III Study for Opdivo Biosimilar BA1104 in China
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced the enrollment of...
China’s Health Authorities Release Third List of 41 Drugs for Recommended Generic Development
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...
CSPC Pharmaceutical Group Gains NMPA Approval for Bivalent COVID-19 mRNA Vaccine Study
CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent pharmaceutical company based in China, has announced...
GenFleet Therapeutics’ SLS009 Receives FDA Fast-Track Status for PTCL Treatment
Shanghai-based biotech GenFleet Therapeutics has announced that its investigational drug SLS009 (GFH009) has received fast-track...
CStone Pharmaceuticals Receives NMPA Approval for Sugemalimab in R/R ENKTL
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received a...
Simcere Pharmaceutical Group Secures Full Approval for Cosela in China
Simcere Pharmaceutical Group (HKG: 2096), a leading pharmaceutical company based in China, has announced that...
Novartis Announces Positive Interim Results for Atrasentan in IgA Nephropathy Phase III Study
Novartis (NYSE: NVS), a global healthcare company, has released interim results from an ongoing Phase...
BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...
Novartis Seeks Access to Takeda’s Business Records Over Confidentiality Concerns
Swiss pharmaceutical giant Novartis (NYSE: NVS) filed a complaint with a US court last week,...